IRVINE, Calif., Sept. 25, 2017 -- Sabra Health Care REIT, Inc. (“Sabra”) (NASDAQ:SBRA) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a price to the public of $21.00 per share. Sabra has granted the underwriters a 30-day option to purchase up to 2,400,000 additional shares of its common stock. Sabra expects to receive net proceeds, after deducting the underwriting discount and Sabra’s estimated offering expenses, of approximately $321.8 million from the offering, or $370.1 million if the underwriters exercise their option to purchase additional shares in full. Sabra expects to issue and deliver the shares of its common stock on or about September 28, 2017, subject to customary closing conditions.
Sabra intends to use the net proceeds from the offering to repay borrowings outstanding on Sabra’s revolving credit facility. Any remaining proceeds to Sabra will be used to fund possible future acquisitions or for general corporate purposes.
Barclays and Citigroup are acting as joint book-running managers and representatives of the underwriters for this offering. BMO Capital Markets, SunTrust Robinson Humphrey, Credit Agricole CIB, MUFG, Raymond James, UBS Investment Bank, Morgan Stanley and Stifel are also acting as joint book-running managers for this offering. Fifth Third Securities and Mizuho Securities are acting as co-managers.
The offering is being conducted pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of any offer to buy the shares of Sabra’s common stock described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering of these securities is being made solely by means of a prospectus supplement and the accompanying prospectus.
Copies of the prospectus supplement and accompanying prospectus for the offering may be obtained by written request to: Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email, at [email protected] or by calling 1-888-603-5847; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 800-831-9146.
CONTACT:
Investor & Media Inquiries:
1-888-393-8248 or [email protected]


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 



